Table 1. Clinical parameters of MPNST cohorts.
| MPNST Cohort 1 MDACC (n=80) |
MPNST Cohort 2 Stanford (n=66) |
MPNST Cohort 3 LUMC (n=16) |
|
|---|---|---|---|
| Age at diagnosis | |||
| -median (range) | 40 (3-73) | n.a. | 28 (15-68) |
| Gender | |||
| -Female | 27 (34%) | n.a. | 9 (56%) |
| -Male | 37 (46%) | n.a. | 7 (44%) |
| -Not available | 16 (20%) | ||
| MPNSTs | |||
| -NF1 associated | 34 (43%) | 43 (65%) | 4 (25%) |
| -Sporadic | 22 (27%) | 21 (32%) | 12 (75%) |
| -Radiation associated | 5 (6%) | 0 (0%) | 0 (0%) |
| -Data n.a. | 19 (24%) | 2 (3%) | 0 (0%) |
| Treatment | |||
| -Resection | 75 (93%) | n.a. | 16 (100%) |
| -Radiotherapy | 6 (8%) | n.a. | 10 (63%) |
| -Chemotherapy | 16 (20%) | n.a. | 4 (25%) |
| -Not available | 48 (60%) | 1 (6%) | |
| Mean survival Time (years) | 4,9 | n.a. | 5,8 |
| Events | 35 (56%) | n.a. | 9 (56%) |
MPNST=malignant peripheral nerve sheath tumor; MDACC= The University of Texas MD Anderson Cancer Center; SUMC= Stanford University Medical Center; LUMC= Leiden University Medical Center. Events = death due to disease. n.a.=not available.